Conjugates Containing Hydrophilic Spacer Linkers

US2016168183A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2016168183-A1
Application numberUS-201514820777-A
CountryUS
Kind codeA1
Filing dateAug 7, 2015
Priority dateJun 25, 2007
Publication dateJun 16, 2016
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Described herein are compositions and methods for use in targeted drug delivery using cell receptor binding drug delivery conjugates containing hydrophilic spacer linkers for use in imaging, diagnosing, and/or treating diseases and disease states caused by pathogenic cell populations.

First claim

Opening claim text (preview).

1 .- 39 . (canceled) 40 . A compound of the formula B-L-A wherein B is a vitamin receptor binding ligand; L is a linker comprising a disulfide and at least one fragment of a formula selected from the group consisting of wherein each d, e, and f is independently an integer from 1 to 5; * is the point of attachment to the rest of the compound; and ** is the disulfide bond; wherein each d′, e′, and f′ is independently an integer from 1 to 5; * is the point of attachment to the rest of the compound; and ** is the disulfide bond; wherein each g and h is independently an integer from 1 to 5; i is an integer from 1 to 4; * is the point of attachment to the rest of the compound; and ** is the disulfide bond; wherein each g′ and h′ is independently an integer from 1 to 5; i′ is an integer from 1 to 4; * is the point of attachment to the rest of the compound; and ** is the disulfide bond; wherein each v, w, x, and y is independently an integer from 1 to 3; each * is the point of attachment to the rest of the compound; and ** is the disulfide bond; wherein each v′, x′, and y′ is independently an integer from 1 to 3; * is the point of attachment to the rest of the compound; and ** is the disulfide bond; and A is an agent selected from the group consisting of a diagnostic, a therapeutic, and an imaging agent; wherein L is covalently bonded to A by a bond selected from the group consisting of amide, ester, disulfide, and imino bonds, and L is covalently bonded to B by an amide or ester bond. 41 . The compound of claim 40 , wherein the disulfide bond comprises 3-dithioalkyloxycarbonylhydrazide. 42 . The compound of claim 40 , wherein the linker and the agent are attached to each other through nitrogen heteroatoms forming a radical of the formula —(NH 2 NH 2 )—. 43 . The compound of claim 40 , wherein the linker comprises one or more independently selected naturally occurring amino acids. 44 . The compound of claim 43 , wherein each of the naturally occurring amino acids is aspartic acid or arginine. 45 . The compound of claim 40 , wherein the linker comprises one or more divalent 1,4-piperazines. 46 . The compound of claim 40 , wherein the ligand is a folate. 47 . The compound of claim 46 , wherein the folate is of the formula wherein each X and Y is independently selected from the group consisting of halo, R 2 , OR 2 , SR 3 , and NR 4 R 5 ; each U, V, and W is independently selected from the group consisting of —(R 6a )C═, —N═, —(R 6a )C(R 7a )—, and —N(R 4a )—; Q is C or CH; T is selected from the group consisting of S, O, N, and —C═C—; each A 1 and A 2 is independently selected from the group consisting of O, S, —C(Z)—, —C(Z)O—, —OC(Z)—, —N(R 4b )—, —C(Z)N(R 4b )—, —N(R 4b )C(Z)—, —OC(Z)N(R 4b )—, —N(R 4b )C(Z)O—, —N(R 4b )C(Z)N(R 5b )—, —S(O)—, —S(O) 2 —, —N(R 4a )S(O) 2 —, —C(R 6b )(R 7b )—, —N(C≡CH)—, —N(CH 2 C≡CH)—, C 1 -C 12 alkylene, and C 1 -C 12 alkyleneoxy; Z is O or S; R 1 is selected from the group consisting of hydrogen, halo, C 1 -C 12 alkyl, and C 1 -C 12 alkoxy; each R 2 , R 3 , R 4 , R 4a , R 4b , R 5 , R 5b , R 6b , and R 7b is independently selected from the group consisting of hydrogen, halo, C 1 -C 12 alkyl, C 1 -C 12 alkoxy, C 1 -C 12 alkanoyl, C 1 -C 12 alkenyl, C 1 -C 12 alkynyl, (C 1 -C 12 alkoxy)carbonyl, and (C 1 -C 12 alkylamino)carbonyl; each R 6 , R 7 , R 6a , and R 7a is independently selected from the group consisting of hydrogen, halo, C 1 -C 12 alkyl, and C 1 -C 12 alkoxy; or R 6 and R 7 are taken together to form a carbonyl group; or R 6a and R 7a are taken together to form a carbonyl group; each p, r, s, and t is independently 0 or 1; and * is the point of attachment to the rest of the compound. 48 . The compound of claim 47 , wherein the folate is of the formula wherein * is the point of attachment to the rest of the compound. 49 . The compound of claim 40 , wherein the agent is a drug. 50 . The compound of claim 40 , wherein the agent is a vinca alkaloid. 51 . The compound of claim 40 , wherein the linker comprises a fragment of the formula each d′, e′, and f′ is independently an integer from 1 to 5; * is the point of attachment to the rest of the compound; and ** is the disulfide bond. 52 . The compound of claim 51 , wherein the compound comprises a fragment of the formula wherein each X and Y is independently selected from the group consisting of halo, R 2 , OR 2 , SR 3 , and NR 4 R 5 ; each U, V, and W is independently selected from the group consisting of —(R 6a )C═, —N═, —(R 6a )C(R 7a )—, and —N(R 4a )—; Q is C or CH; T is selected from the group consisting of S, O, N, and —C═C—; each A 1 and A 2 is independently selected from the group consisting of O, S, —C(Z)—, —C(Z)O—, —OC(Z)—, —N(R 4b )—, —C(Z)N(R 4b )—, —N(R 4b )C(Z)—, —OC(Z)N(R 4b )—, —N(R 4b )C(Z)O—, —N(R 4b )C(Z)N(R 5b )—, —S(O)—, —S(O) 2 —, —N(R 4a )S(O) 2 —, —C(R 6b )(R 7b )—, —N(C≡CH)—, —N(CH 2 C≡CH)—, C 1 -C 12 alkylene, and C 1 -C 12 alkyleneoxy; Z is O or S; R 1 is selected from the group consisting of hydrogen, halo, C 1 -C 12 alkyl, and C 1 -C 12 alkoxy; each R 2 , R 3 , R 4 , R 4a , R 4b , R 5 , R 5b , R 6b , and R 7b is independently selected from the group consisting of hydrogen, halo, C 1 -C 12 alkyl, C 1 -C 12 alkoxy, C 1 -C 12 alkanoyl, C 1 -C 12 alkenyl, C 1 -C 12 alkynyl, (C 1 -C 2 alkoxy)carbonyl, and (C 1 -C 12 alkylamino)carbonyl; each R 6 , R 7 , R 6a , and R 7a is independently selected from the group consisting of hydrogen, halo, C 1 -C 12 alkyl, and C 1 -C 12 alkoxy; or R 6 and R 7 are taken together to form a carbonyl group; or R 6a and R 7a are taken together to form a carbonyl group; each d′, e′, and f′ is independently an integer from 1 to 5; each p, r, s, and t is independently 0 or 1; and ** is the disulfide bond. 53 . The compound of claim 40 , wherein the linker comprises a fragment of the formula wherein each d, e, and f is independently an integer from 1 to 5;

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2016168183A1 cover?
Described herein are compositions and methods for use in targeted drug delivery using cell receptor binding drug delivery conjugates containing hydrophilic spacer linkers for use in imaging, diagnosing, and/or treating diseases and disease states caused by pathogenic cell populations.
Who is the assignee on this patent?
Endocyte Inc
What technology area does this patent fall under?
Primary CPC classification C07H15/24. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Jun 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).